NSCLC STAGE IV
Clinical trials for NSCLC STAGE IV explained in plain language.
Never miss a new study
Get alerted when new NSCLC STAGE IV trials appear
Sign up with your email to follow new studies for NSCLC STAGE IV, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a dose increase control lung cancer that Isn't shrinking?
Disease control Not yet recruitingThis study tests whether a higher dose (160 mg) of the drug firmonertinib can improve outcomes for people with advanced EGFR-mutant non-small cell lung cancer whose tumors have stayed stable but not shrunk after 8 weeks on the standard 80 mg dose. About 28 adults aged 18-75 with …
Matched conditions: NSCLC STAGE IV
Phase: PHASE2 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New drug cocktail targets tough lung cancer mutation
Disease control Not yet recruitingThis early-phase trial is testing a combination of two drugs—a targeted pill (Glecirasib) and an immunotherapy infusion (Ivonescimab)—as a first treatment for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. The study will first find the saf…
Matched conditions: NSCLC STAGE IV
Phase: PHASE1, PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC